Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Sophie Saxton completed her undergraduate degree in Pharmacology (2013) and Master of Research degree in Cardiovascular Sciences (2014) at the University of Manchester.
Since then she has been working on her PhD in Cardiovascular medicine, studying the role of the sympathetic nervous system in perivascular adipose tissue function.
Healthy perivascular adipose tissue (PVAT) exerts an anti-contractile effect on resistance arteries which is vital in regulating arterial tone.
Activation of β3- adrenoceptors by the neurotransmitter, noradrenaline (NA), may be implicated in the anti-contractile effect of PVAT. In obesity the anti-contractile effect is lost, leading to the development of hypertension.
Accordingly, we have investigated the effect of sympathetic nerve stimulation (SNS) within healthy and obese PVAT on the anti-contractile effect.
Electrical field stimulation (EFS) profiles of healthy C57 mouse mesenteric arteries were characterised using wire myography. During EFS PVAT elicits a reproducible anti-contractile effect. To demonstrate the release of an anti-contractile factor, the solution surrounding stimulated exogenous PVAT was transferred to a PVAT denuded vessel. Post-transfer contractility is significantly reduced confirming that stimulated PVAT releases a transferable anti-contractile factor. Sympathetic denervation of PVAT using 6-hydroxydopamine completely abolished the anti-contractile effect. β3-adrenoceptor antagonist SR59203A reduced the anti-contractile effect, although the fat remained overall anti-contractile.
When the antagonist was used in combination with an OCT-3 inhibitor; corticosterone, the anti-contractile effect was completely abolished, demonstrating that the effect is due to both the release of an anti-contractile factor via β3-adrenoceptor activation, and a result of PVAT acting as a reservoir for NA. The effects of an adiponectin receptor 1 blocking peptide were tested, and the anti-contractile effect was significantly reduced, suggesting that the anti-contractile factor may be adiponectin.
A model of obesity was established, and the EFS profiles of ±PVAT vessels were characterised. The anti-contractile effect was completely absent, and could not be rescued using a β3-adrenoceptor agonist; CL-316,243, suggesting that in obesity these receptors are downregulated.
These results demonstrate the roles of PVAT are two-fold. First of all, SNS in PVAT triggers the release of adiponectin via β3-adrenoceptor activation. Secondly PVAT acts as a reservoir for NA, preventing it from reaching the vessel and causing contraction. In obesity, β3-adrenoceptors may have become downregulated, resulting in a loss of function, and leading to hypertension.
© 2017 European Society of Cardiology. All rights reserved